Immunoassays are an essential analytical tool used throughout the development and manufacturing of cell and gene therapies to evaluate viral vector titers and process impurities. The two most commonly used vehicles for delivery of gene therapies into mammalian cells are adeno-associated virus (AAV) and lentiviral vectors, and consequently AAV titer and lentiviral titer ELISA assays are commonly developed for this purpose. However, lengthy assay development and sample analysis times using traditional ELISA methods often cause delays in program schedules. 

The use of robust immunoassay platforms for analysis in gene therapy development can streamline production. The automated Gyrolab^® platform significantly reduces time to results, sample volume, and improves data quality for AAV- and lentivirus-based gene therapy immunoassays during development, and is ideally suited for compressed cell and gene therapy development timelines.